Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intron A Plus BCG for Superficial Bladder Cancer
NCT00004122Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jul 1999
- Primary completion
- Apr 2001
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon alfa-2b in bladder cancer, sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Efficacy of BCG combined with interferon alfa 2b. Started Jul 1999; status: completed.
02
Drugs
interferon alfa-2b
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00004122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004122.